200 related articles for article (PubMed ID: 37330371)
1. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
Puthanakit T; Chokephaibulkit K; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
Vaccine; 2023 Jul; 41(31):4541-4553. PubMed ID: 37330371
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K; Puthanakit T; Bhat N; Mansouri S; Tang Y; Lapphra K; Rungmaitree S; Anugulruengkitt S; Jantarabenjakul W; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Chinwangso P; Suwitruengrit L; van den Biggelaar AHJ; Viviani S; Pham HT; Innis BL
Vaccine; 2022 Apr; 40(15):2352-2361. PubMed ID: 34789403
[TBL] [Abstract][Full Text] [Related]
3. Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
Chokephaibulkit K; Puthanakit T; Chaithongwongwatthana S; Bhat N; Tang Y; Anugulruengkitt S; Chayachinda C; Anuwutnavin S; Lapphra K; Rungmaitree S; Tawan M; Andi-Lolo I; Holt R; Fortuna L; Kerdsomboon C; Yuwaree V; Mansouri S; Thai PH; Innis BL
Vaccine; 2024 Jan; 42(2):383-395. PubMed ID: 38061956
[TBL] [Abstract][Full Text] [Related]
4. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
8. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
9. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
12. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
[TBL] [Abstract][Full Text] [Related]
13. Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Fortuna L; Chaithongwongwatthana S; Soonthornworasiri N; Spiegel J; Wijagkanalan W; Mansouri S; van den Biggelaar AHJ; Pham HT
Vaccine; 2020 Dec; 38(51):8194-8199. PubMed ID: 33176935
[TBL] [Abstract][Full Text] [Related]
14. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
[TBL] [Abstract][Full Text] [Related]
17. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
19. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
[TBL] [Abstract][Full Text] [Related]
20. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
